Ranibizumab is an active ingredient from the group of VEGF inhibitors. Ranibizumab is a humanised recombinant monoclonal antibody fragment (Fab V2) of the monoclonal antibody Bevacizumab. It is produced by means of recombinant DNA from the bacterium Escherichia coli.